Certifications

For Certification, a technology must have demonstrated confidence of continued effectiveness: i.e., it will perform as intended, conform to the seller’s specifications, and is safe for use as intended. In addition to the benefits provided under Designation, Certification allows Sellers of antiterrorism technologies to assert the Government Contractor Defense that immunizes Sellers from liability for claims arising from acts of terrorism. Technologies that receive Certification will be also placed on an Approved Products List for Homeland Security. Designation is a prerequisite for Certification.




Company/Technology

Ameristar Perimeter Security USA Inc.

Approved: December 14, 2016 | Expires: January 31, 2022

Ameristar Perimeter Security USA Inc., provides Impasse & Impasse II High Security Palisade Fence (the “Technology”). The Technology is high security fencing intended to deter, delay, or prevent intruders from gaining access to an asset or from launching attacks from the area immediately outside a facility’s perimeter. The Technology also includes Technology-related accessories, warranty, guidelines for maintaining the Technology, and recommendations for qualified installers.

SAFRAN USA, Inc., Morpho Detection, Inc., and Morpho Detection International, LLC

Approved: December 14, 2016 | Expires: January 31, 2022

SAFRAN USA, Inc., Morpho Detection, Inc., and Morpho Detection International, LLC provide Integrated Logistics Support (“ILS”) Services (the “Technology”). The Technology is the establishment, implementation, and maintenance of an ILS program to sustain Government-certified Explosives Detection Systems (“EDS”), Multiplexing Equipment (“MUX”), and associated Uninterruptible Power Supply (“UPS”) as deployed and operated by the Transportation Security Administration (“TSA”).

BlastGard International, Inc.

Approved: November 10, 2016 | Expires: November 30, 2021

BlastGard International, Inc. provides BlastWrap® (the "Technology"). The Technology can be deployed to mitigate (i.e., contain) the effects of an explosion or as a protective layer to absorb energy and possibly protect assets from damage caused by an external explosion.

Smiths Detection Inc.

Approved: October 26, 2016 | Expires: November 30, 2021

Smiths Detection, Inc. provides HI-SCAN CCX-RAY (the “Technology”). The Technology is a collection of X-ray inspection systems used to screen cargo and freight packages. The devices use transmission X-ray imaging methodology, together with software-based image analysis, to detect potential threats and present them to the operator through a graphical interface. The Technology also includes software, installation, life cycle support, training, warrantee program, manuals, bulletins, and other communications.

L-3 Communications Security and Detection Systems

Approved: October 26, 2016 | Expires: November 30, 2021

L-3 Communications Security and Detection Systems, Inc. and L-3 Communications Corporation provide the ProVision™ ATD and ProVision™ 2 (the “Technology”). The Technology is used at security checkpoints in airports, courthouses, correctional institutions, and other government and commercial facilities. It uses millimeter-wave scanning technology to produce three-dimensional images of subjects to detect concealed threat objects on scanned subjects. SAFETY Act protections apply to models of the Technology that use the Automated Target Detection (“ATD”) software and those models have passed field testing by the U.S. Transportation Security Administration.

Meridian Medical Technologies, Inc.

Approved: September 27, 2016 | Expires: October 31, 2021

Meridian Medical Technologies, Inc. provides ATNAA, Diazepam, DuoDote®, Pralidoxime Chloride, AtroPen®, Morphine Auto-injectors (the “Technology”). The Technology is a series of ready-to-use, pre-filled auto-injectors intended for the treatment of chemical nerve agent exposure or for the management of pain. The Technology is approved for use by the U.S. Food and Drug Administration (“FDA”). It also includes packaging, stockpile storage of sterile auto-injector assemblies, stockpile storage of medical solutions, training auto-injectors, and the associated use protocols, labeling, and package inserts.

Mistral Security Inc.

Approved: September 12, 2016 | Expires: October 31, 2021

Mistral Security Inc. provides Blast Containment Receptacles (the “Technology”). The Technology is trash receptacles designed to absorb blast energy and resist fragments of an explosive device concealed within the receptacle.

Emergent Protective Products USA, Inc. and Emergent BioSolutions Inc.

Approved: September 09, 2016 | Expires: September 30, 2021

Emergent Protective Products USA, Inc. and Emergent BioSolutions Inc. provide Reactive Skin Decontamination Lotion Kit (“RSDL” or the “Technology”). The Technology is a formulation for the treatment of skin that has been contaminated with toxic chemical agents. The Technology is formulated to neutralize and/or remove the following chemical warfare agents: (a) nerve agents, including many organophosphate-pesticides; (b) blister agents, and (c) Trichothecene Mycotoxin (T-2) toxins that have come into contact with exposed skin.

Unisys Corporation

Approved: September 09, 2016 | Expires: September 30, 2021

Unisys Corporation provides to the U.S. Customs and Border Protection (“CBP”) Targeting & Analysis Systems Program Directorate (“TASPD”) Support Services for Selectivity and Targeting Systems Software Applications (the “Technology”). The Technology consists of a set of services used to upgrade, modify, enhance, operate, and maintain Selectivity and Targeting Systems Software Applications in response to evolving technologies, threats, and mission requirements.

Emergent BioDefense Operations Lansing LLC

Approved: August 26, 2016 | Expires: September 30, 2021

Emergent BioDefense Operations Lansing LLC provides BioThrax® (the “Technology”). The Technology is a sterile liquid suspension made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. The Technology is U.S. Food and Drug Administration (“FDA”)-licensed for active immunization of individuals between 18 and 65 years of age to prevent disease caused by Bacillus anthracis. The Technology is to be administered and used in a manner consistent with its FDA licensing as a pre-exposure prophylaxis or as directed by the U.S. Government as a post-exposure prophylaxis. The Technology also includes manufacturing, testing, labeling, packaging, and storage of BioThrax®, as well as the associated technical documents and manuals.